Fredun Pharma Reports Positive Financial Results for Q2 2024, But Rising Interest Cost Raises Concerns

Fredun Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.

According to the financial report, Fredun Pharma has shown positive performance in the second quarter of the fiscal year 2024-2025. The company's score has decreased from 9 to 6 in the last three months, indicating a positive trend.

The company's Profit After Tax (PAT) for the half-yearly period has grown by 32.49% year on year, reaching Rs 8.40 crore. The net sales for the quarter have also shown a growth of 30.95% year on year, reaching Rs 107.35 crore. The operating profit (PBDIT) for the quarter is at its highest in the last five quarters, standing at Rs 13.94 crore. The Profit Before Tax less Other Income (PBT) for the quarter has also shown a positive trend, reaching its highest at Rs 7.58 crore and growing by 31.37% year on year.

However, there are some areas that need improvement for Fredun Pharma. The interest cost for the quarter has increased by 35.81% quarter on quarter, reaching Rs 5.31 crore. This signifies increased borrowings for the company, which may have a negative impact on its financials.

Overall, Fredun Pharmaceuticals has shown positive financial performance in the recent quarter, with a strong growth in PAT, net sales, and operating profit. However, the rising interest cost is a cause for concern and the company may need to address this issue in the future. Investors should keep a close eye on the company's financials and make informed decisions based on the available data.